Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorStony Brook University

About this trial

The goal of this clinical trial is to learn if the OTC supplement, hydrogen water, works to treat the fatigue-related symptoms and functional limitations in adults with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). It will also examine if heart rate variability (HRV) can be used to predict who will benefit from the hydrogen water treatment. The main questions it aims to answer are:

Does the OTC supplement, hydrogen water, work to reduce the fatigue-related symptoms and improve functioning in participants who have ME/CFS?

Can HRV be used to predict who will benefit from treatment with hydrogen water?

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Single group

Treatments tested in this trial

  • Hydrogen water which is prepared from an OTC supplement.

    Dietary supplement

    The intervention is hydrogen water which is prepared from an OTC supplement. It involves measurement of heart rate variability.

Treatment groups

50 Participants
are divided into 1 treatment group
Group A: Hydrogen water standard dosageExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Fatigue Severity Scale

This is a validated self-report measure of the effect of fatigue on functioning.

Time frame
12 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.